摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 4-(1-(5-chloro-2-(3-(4-fluoro-3-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate | 1380754-62-0

分子结构分类

中文名称
——
中文别名
——
英文名称
methyl 4-(1-(5-chloro-2-(3-(4-fluoro-3-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate
英文别名
Methyl 4-[1-[[5-chloro-2-[3-[4-fluoro-3-(trifluoromethyl)phenoxy]azetidin-1-yl]pyridine-3-carbonyl]amino]cyclopropyl]benzoate
methyl 4-(1-(5-chloro-2-(3-(4-fluoro-3-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate化学式
CAS
1380754-62-0
化学式
C27H22ClF4N3O4
mdl
——
分子量
563.936
InChiKey
WLIJUGFGSBKLIQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.4
  • 重原子数:
    39
  • 可旋转键数:
    8
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    80.8
  • 氢给体数:
    1
  • 氢受体数:
    10

文献信息

  • PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS
    申请人:Borriello Manuela
    公开号:US20130261100A1
    公开(公告)日:2013-10-03
    The invention relates pyridine amide derivative of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 are independently hydrogen, linear o branched (C1-C3)alkyl or joined together they form a cyclopropyl ring; R is independently selected from the group consisting of halogens and trifluoromethyl and p is 1, 2 or 3; A is C or N; E is a group of formula (B) or (C), wherein B is C(O)OH, C(O)O(C1-C3)alkyl, and C is selected from the group consisting of formula (I) m is 1,2 or 3, n is 0 or 1, W is —O—, —O(C1-C3 alkyl)-; —(C1-C3 alkyl)O—; —C(O)—; —C(═N—O(C1-C3 alkyl))-; —NH— or —NH(C1-C3alkyl)-; Ar is phenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, methyl, —NH(C1-C3alkyl)-; —N(C1-C3alkyl)(C1-C3alkyl)-, a from 5 to 7 membered heterocyclic ring containing one nitrogen atom which is covalently bonded to Ar and optionally containing one or two heteroatoms selected from N, O and S; and a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from S, O e N, such heteroaromatic ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl. The compounds of the invention could be used for manufacturing a medicament for the treatment of pathologies which require the use of an antagonist of the EP4 receptor, such as the treatment of acute and chronic pain, inflammatory pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, endometriosis and migraine.
    该发明涉及式(I)的吡啶酰胺衍生物或其药学上可接受的盐,其中R1和R2独立地为氢、直链或支链(C1-C3)烷基,或者它们结合在一起形成环丙基环;R独立地选自卤素和三甲基的群,p为1、2或3;A为C或N;E为式(B)或(C)的基团,其中B为C(O)OH、C(O)O(C1-C3)烷基,C选自式(I)的群,m为1、2或3,n为0或1,W为—O—、—O(C1-C3烷基)-、—(C1-C3烷基)O—、—C(O)—、—C(═N—O(C1-C3烷基))-、—NH—或—NH(C1-C3烷基)-;Ar为苯基,可选地取代一个或多个取代基,选自卤素、三甲基、三甲氧基、甲基、—NH(C1-C3烷基)-、—N(C1-C3烷基)(C1-C3烷基)-,a为含有一个氮原子的5至7元杂环,与Ar共价键合,可选地含有一个或两个来自N、O和S的杂原子;以及含有1至3个来自S、O和N的杂原子的5-或6元杂芳环,该杂芳环被选自(C1-C3)烷基、(C3-C5)环烷氧基、(C1-C3)烷基羰基的一或两个取代基取代。该发明的化合物可用于制造用于治疗需要使用EP4受体拮抗剂的病理病变的药物,例如治疗急性和慢性疼痛、炎症性疼痛、骨关节炎、与炎症相关的疾病如关节炎、类风湿性关节炎、癌症、子宫内膜异位症和偏头痛。
  • [EN] PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE PYRIDINAMIDE EN TANT QU'ANTAGONISTES DE RÉCEPTEUR EP4
    申请人:ROTTAPHARM SPA
    公开号:WO2012076063A1
    公开(公告)日:2012-06-14
    The invention relates pyridine amide derivative of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently hydrogen, linear o branched (C1-C3)alkyl or joined together they form a cyclopropyl ring; R is independently selected from the group consisting of halogens and trifluoromethyl and p is 1, 2 or 3; A is C or N; E is a group of formula (B) or (C), wherein B is C(O)OH, C(O)O(C1-C3)alkyl, and C is selected from the group consisting of formula (I) m is 1,2 or 3, n is 0 or 1, W is -O-, -O(C1-C3 alkyl)-; -(C1-C3 alkyl)O-; -C(O)-; -C(=N-O(C1-C3 alkyl))-; -NH- or -NH(C1-C3alkyl)-; Ar is phenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, methyl, -NH(C1-C3alkyl)-; -N(C1-C3alkyl)(C1-C3alkyl)-, a from 5 to 7 membered heterocyclic ring containing one nitrogen atom which is convalently bonded to Ar and optionally containing one or two heteroatoms selected from N, O and S; and a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from S, O e N, such heteroaromatic ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl. The compounds of the invention could be used for manufacturing a medicament for the treatment of pathologies which require the use of an antagonist of the EP4 receptor, such as the treatment of acute and chronic pain, inflammatory pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid artrhritis, cancer, endometriosis and migraine.
    该发明涉及式(I)的吡啶酰胺衍生物或其药学上可接受的盐,其中R1和R2独立地为氢、直链或支链(C1-C3)烷基,或者它们结合在一起形成环丙基环;R独立地选自卤素和三甲基的群,p为1、2或3;A为C或N;E为式(B)或(C)的基团,其中B为C(O)OH、C(O)O(C1-C3)烷基,C选自式(I)的群,m为1、2或3,n为0或1,W为-O-、-O(C1-C3烷基)-、-(C1-C3烷基)O-、-C(O)-、-C(=N-O(C1-C3烷基))-、-NH-或-NH(C1-C3烷基)-;Ar为苯基,可选择地取代一个或多个取代基,选自卤素、三甲基、三甲氧基、甲基、-NH(C1-C3烷基)-、-N(C1-C3烷基)(C1-C3烷基)-,a为含有一个氮原子的5至7元杂环环,与Ar共价键合,可选择地含有一个或两个来自N、O和S的杂原子;以及含有1至3个来自S、O和N的杂原子的5-或6元杂芳环,该杂芳环被选自(C1-C3)烷基、(C3-C5)环烷氧基、(C1-C3)烷基羰基的一或两个取代基取代。该发明的化合物可用于制造用于治疗需要使用EP4受体拮抗剂的病理的药物,例如治疗急性和慢性疼痛、炎症性疼痛、骨关节炎、关节炎、类风湿性关节炎、癌症、子宫内膜异位症和偏头痛。
  • US8828987B2
    申请人:——
    公开号:US8828987B2
    公开(公告)日:2014-09-09
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (反式)-4-壬烯醛 (双(2,2,2-三氯乙基)) (乙腈)二氯镍(II) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (±)17,18-二HETE (±)-辛酰肉碱氯化物 (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (s)-2,3-二羟基丙酸甲酯 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 ([2-(萘-2-基)-4-氧代-4H-色烯-8-基]乙酸) ([1-(甲氧基甲基)-1H-1,2,4-三唑-5-基](苯基)甲酮) (Z)-5-辛烯甲酯 (Z)-4-辛烯醛 (Z)-4-辛烯酸 (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-(+)-5,5'',6,6'',7,7'',8,8''-八氢-3,3''-二叔丁基-1,1''-二-2-萘酚,双钾盐 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-盐酸沙丁胺醇 (S)-溴烯醇内酯 (S)-氨氯地平-d4 (S)-氨基甲酸酯β-D-O-葡糖醛酸 (S)-8-氟苯并二氢吡喃-4-胺 (S)-7,7-双[(4S)-(苯基)恶唑-2-基)]-2,2,3,3-四氢-1,1-螺双茚满 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(((2,2-二氟-1-羟基-7-(甲基磺酰基)-2,3-二氢-1H-茚满-4-基)氧基)-5-氟苄腈 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-2-N-Fmoc-氨基甲基吡咯烷盐酸盐 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯